Grannus BioSciences Ltd (GBL), a bio-pharmaceutical company developing novel products to control inflammatory and hyperproliferative disorders, announced today the appointment of EGeen AS, a subsidiary of EGeen International, as CRO for the Company’s clinical development activities. Under the terms of the agreement, Grannus will utilize EGeen for the clinical testing of its lead biologic and small molecule therapeutics in Phase I and II human clinical trials respectively against a number of dermatologic diseases and conditions.
